|
25 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
1 Trial |
|
217 News |
|
| «12345 |
- | Aqupla (nedaplatin) / Simcere
Enrollment open, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 28, 2012
P3, N=372, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting
- || Aqupla (nedaplatin) / Simcere
New P3 trial, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 26, 2012
P3, N=372, Recruiting, Sponsor: Sun Yat-sen University
- Conmana (icotinib) / Betta Pharma
Enrollment open: Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 16, 2012
P1/2, N=60, Recruiting, Sponsor: Taizhou Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | pemetrexed / Generic mfg.
Enrollment change, Metastases: Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy (clinicaltrials.gov) - Feb 13, 2012
P2, N=35, Completed, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting N=66 --> 35
- | pemetrexed / Generic mfg.
Trial completion, Metastases: Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy (clinicaltrials.gov) - Feb 13, 2012
P2, N=35, Completed, Sponsor: Sun Yat-sen University
N=66 --> 35 Recruiting --> Completed
- | Conmana (icotinib) / Betta Pharma
New P1/2 trial: Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 12, 2012
P1/2, N=60, Recruiting, Sponsor: Taizhou Hospital
- Enrollment open, Metastases: New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer (clinicaltrials.gov) - Feb 8, 2012
P=N/A, N=68, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, IO biomarker, Metastases: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (clinicaltrials.gov) - Feb 6, 2012
P2, N=88, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
New P1 trial, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Feb 5, 2012
P1, N=4, Terminated, Sponsor: Stanford University
- ||||||| zoledronic acid / Generic mfg.
Trial completion: To Evaluate the Efficacy of ZOMETA (clinicaltrials.gov) - Jan 30, 2012
P3, N=60, Completed, Sponsor: Sun Yat-sen University
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- |||| 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy: Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents (clinicaltrials.gov) - Jan 26, 2012
P2, N=75, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P1 trial, Metastases: FMTN-I-LNPC: Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 26, 2011
P1, N=21, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- New P1/2 trial: Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 3, 2011
P1/2, N=40, Completed, Sponsor: Xiangya Hospital of Central South University
- || New P3 trial: Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients (clinicaltrials.gov) - Sep 21, 2011
P3, N=94, Completed, Sponsor: Instituto Nacional de Cancer, Brazil
- | Enrollment change, Metastases: A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer (clinicaltrials.gov) - Aug 8, 2011
P2, N=20, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed N=35 --> 20
- | Trial completion, Metastases: A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer (clinicaltrials.gov) - Aug 8, 2011
P2, N=20, Completed, Sponsor: University Health Network, Toronto
N=35 --> 20 Active, not recruiting --> Completed